09/690,353

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:SSSPTA1208DXJ
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS 3	Feb 06	Engineering Information Encompass files have new names
NEWS 4	Feb 16	TOXLINE no longer being updated
NEWS 5	Apr 23	Search Derwent WPINDEX by chemical structure
NEWS 6	Apr 23	PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7	May 07	DGENE Reload
NEWS 8	Jun 20	Published patent applications (A1) are now in USPATFULL
NEWS 9	JUL 13	New SDI alert frequency now available in Derwent's DWPI and DPCI
NEWS 10	Aug 23	In-process records and more frequent updates now in MEDLINE
NEWS 11	Aug 23	PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
NEWS 12	Aug 23	Adis Newsletters (ADISNEWS) now available on STN
NEWS 13	Sep 17	IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH
NEWS 14	Oct 09	Korean abstracts now included in Derwent World Patents Index
NEWS 15	Oct 09	Number of Derwent World Patents Index updates increased
NEWS 16	Oct 15	Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS 17	Oct 22	Over 1 million reactions added to CASREACT
NEWS 18	Oct 22	DGENE GETSIM has been improved
NEWS 19	Oct 29	AAASD no longer available

NEWS EXPRESS	August 15 CURRENT WINDOWS VERSION IS V6.0c, CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP), AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:29:35 ON 02 NOV 2001

=> fil reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.30	0.30

```
FILE 'REGISTRY' ENTERED AT 14:30:55 ON 02 NOV 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:     1 NOV 2001  HIGHEST RN 366444-38-4
DICTIONARY FILE UPDATES:    1 NOV 2001  HIGHEST RN 366444-38-4

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER see
HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> e cobalamin?
E1            2     COBALACTONE/BI
E2          343     COBALAMIN/BI
E3            0 --> COBALAMIN?/BI
E4           21     COBALAMINE/BI
E5            1     COBALAMINELACTAM/BI
E6            1     COBALAMINMONO/BI
E7            1     COBALAMINMONOCARBOXYL/BI
E8            1     COBALAMINMONOCARBOXYLIC/BI
E9            2     COBALAMINSULFONIC/BI
E10           1     COBALAMINTRI/BI
E11           1     COBALAMINTRICARBOXYL/BI
E12           1     COBALAMINTRICARBOXYLIC/BI

=> s e2
L1          343 COBALAMIN/BI

=> d
```

L1 ANSWER 1 OF 343 REGISTRY COPYRIGHT 2001 ACS
RN 357492-04-7 REGISTRY
CN **349aa long cobalamin biosynthesis protein cobD (Sulfolobus tokodaii strain 7 gene ST2342) (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN GenBank AP000989-derived protein GI 15623463
FS PROTEIN SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

```
=> fil .search
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY     SESSION
FULL ESTIMATED COST                                         5.61        5.91

FILE 'MEDLINE' ENTERED AT 14:31:28 ON 02 NOV 2001

FILE 'CAPLUS' ENTERED AT 14:31:28 ON 02 NOV 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 14:31:28 ON 02 NOV 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 14:31:28 ON 02 NOV 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 14:31:28 ON 02 NOV 2001
COPYRIGHT (C) 2001 Elsevier Science B.V.  All rights reserved.

=> s l1
L2        50399 L1

<------User Break------>
u
SEARCH ENDED BY USER

=> s l2 and (peptide? or polypeptide? or amino(w)acid?)
   2 FILES SEARCHED...
   4 FILES SEARCHED...
L3         3794 L2 AND (PEPTIDE? OR POLYPEPTIDE? OR AMINO(W) ACID?)

=> s l3 and (radionuclide? or radiolabel? or radioactiv? or radioisotop?)
L4          208 L3 AND (RADIONUCLIDE? OR RADIOLABEL? OR RADIOACTIV? OR RADIOISO
                TOP?)

=> s l4 and (chelat? or ligand?)
L5           72 L4 AND (CHELAT? OR LIGAND?)

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6           68 DUP REM L5 (4 DUPLICATES REMOVED)

=> d ibib ab 1-
YOU HAVE REQUESTED DATA FROM 68 ANSWERS - CONTINUE? Y/(N):y
```

L6 ANSWER 1 OF 68 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:300853 CAPLUS
DOCUMENT NUMBER: 134:223118
TITLE: Cobalamin conjugates useful as tumor imaging and therapeutic agents
INVENTOR(S): Hogenkamp, Henricus P. C.; Collins, Douglas A
PATENT ASSIGNEE(S): Mayo Foundation for Medical Education and Research, USA; Regents of the University of Minnesota
SOURCE: PCT Int. Appl., 46 pp
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001008850	A1	20010426	WO 2000-US10098	200004 15

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-159753 A2 19991015
OTHER SOURCE(S): MARPAT 134:223118
AB The invention provides detectably labeled cobalamin derivs. which are useful for medical treatment and diagnosis. Cobalamin conjugates have **peptides** or **amino acids** linked to metal **radionuclide chelates** or nonmetallic **radionuclides**.
REFERENCE COUNT: 4
REFERENCE(S): (1) Biotech Australia Pty Ltd; WO 9437613 A 1994 CAPLUS
(2) Collins, D; US 5739313 A 1998 CAPLUS
(3) Collins, D; WO 0062802 A 2000 CAPLUS
(4) Grimson, C; WO 9808859 A 1998 CAPLUS

L6 ANSWER 2 OF 68 USPATFULL
ACCESSION NUMBER: 2003:163361 USPATFULL
TITLE: Discrete-length polyethylene glycols
INVENTOR(S): Wilbur, D Scott, Edmonds, WA, United States
Pathare, Pradip M., Seattle, WA, United States
PATENT ASSIGNEE(S): The University of Washington, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6594697	B1	20030325
APPLICATION INFO.:	US 1998-62286		19980417 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1996-US16765, filed on 18 Oct 1996		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-5599	19951019 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Padmanabhan, Sreeni	
LEGAL REPRESENTATIVE:	Christensen O'Connor Johnson & Kindness PLLC	
NUMBER OF CLAIMS:	38	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 14 Drawing Page(s)	
LINE COUNT:	1072	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides discrete-length polyethylene glycol and polyethylene glycol containing compounds and methods for their preparation.

L6 ANSWER 3 OF 68 USPATFULL
ACCESSION NUMBER: 2001:152712 USPATFULL
TITLE: nrdG
INVENTOR(S): Black, Michael Terence, Chester Springs, PA, United States
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6287804	B1	20010911
APPLICATION INFO.:	US 1998-40213		19980317 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Martinell, James		
LEGAL REPRESENTATIVE:	Gimmi, Edward R., Deibert, Thomas S., King, William T		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2108		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides nrdG **polypeptides** and polynucleotides encoding nrdG **polypeptides** and methods for producing such **polypeptides** by recombinant techniques. Also provided are methods for utilizing nrdG **polypeptides** to screen for antibacterial compounds.

L6 ANSWER 4 OF 68 USPATFULL
ACCESSION NUMBER: 2001:131279 USPATFULL
TITLE: Compositions of cobalamin and related corrinoids, and uses thereof
INVENTOR(S): Zerilli, William J., 78 Hibbert St., Arlington, MA, United States 02154
Brennan, Thomas F., 44 A Gail Dr., Nyack, NY, United States 10960

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6274564	B1	20010814
APPLICATION INFO.:	US 1997-936781		19970917 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-25398	19960918 (60)
	US 1997-41750	19970328 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Travers, Russell	
LEGAL REPRESENTATIVE:	Lahive & Cockfield, LLP	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1907	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel compositions cobalamin and related corrinoids, and uses thereof, are disclosed. The novel compositions include a corrin, a first **amino acid** having a side chain which includes a basic or positively charged moiety, and a second **amino acid** with an uncharged side chain which includes at least one heteroatom. The compositions are useful for, inter alia, treatment of cobalamin deficiency.

L4 ANSWER 5 OF 68 USPATFULL
ACCESSION NUMBER: 2001:98064 USPATFULL
TITLE: Ribb
INVENTOR(S): Black, Michael Terance, Chester Springs, PA, United States
Shilling, Lisa Kathleen, Newtown, PA, United States
Stodola, Robert King, Flourtown, PA, United States
Warren, Richard Lloyd, Blue Bell, PA, United States
Kosmatka, Anna Lisa, Doylestown, PA, United States
Nicholas, Richard Oakley, Collegeville, PA, United States
Palmer, Leslie Marie, Audubon, PA, United States
Lonetto, Michael Arthur, Collegeville, PA, United States
Fedon, Jason Craig, Strafford, PA, United States
Hodgson, John Edward, Malvern, PA, United States
Knowles, David Justin Charles, BoroughBridge, United Kingdom
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
SmithKline Beecham plc, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6252044	B1	20010626
APPLICATION INFO.:	US 1997-977555		19971125 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-24022	19960816 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Mannifield, Nita	
LEGAL REPRESENTATIVE:	Given, Edward R., Diebert, Thomas S., King, William T.	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3599	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides ribB **polypeptides** and polynucleotides encoding ribB **polypeptides** and methods for producing such **polypeptides** by recombinant techniques. Also provided are methods for utilizing ribB **polypeptides** to screen for antibacterial compounds.

L4 ANSWER 6 OF 68 USPATFULL
ACCESSION NUMBER: 2001:97419 USPATFULL
TITLE: Method and a system for enhanced in vivo clearance of diagnostic and/or therapeutic agents by extracorporeal depletion, and the use of said agents for said purpose
INVENTOR(S): Nilsson, Rune, Lund, Sweden
Lundgren, Lars, Lund, Sweden
Norrgren, Kristina, ÄNG:karp, Sweden
Sandberg, Bengt, Lund, Sweden
Sjogren, Hans Olof, Lund, Sweden
Strand, Svein-Erik, Lund, Sweden
PATENT ASSIGNEE(S): Mitra Medical Technology AB, Lund, Sweden (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6231194	B1	20010626
APPLICATION INFO.:	WO 9212730		19930806
	US 1993-92047		19931012 (8)
	WO 1992-SE20		19920115
			19931012 PCT 371 date
			19931012 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1991-142	19910117
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Witz, Jean C.	
LEGAL REPRESENTATIVE:	Swanson & Bratschun L	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	656	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method and a system is described for reducing non-target levels of specific molecules intended for diagnostic and/or therapeutic applications to vertebrate hosts, wherein said molecules are administered to a vertebrate host and kept therein for a certain time in order to be concentrate to the target by being attached thereto. The molecules which are not attached to the target are removed from the blood circulation system or at least reduced to a lower concentration by passing the blood through an extra-corporeal device.

L4 ANSWER 7 OF 68 USPATFULL
ACCESSION NUMBER: 2001:17971 USPATFULL
TITLE: Transcobalamin mediated transport of vitamine B12 in antrinsic factor or receptor deficient patient
INVENTOR(S): Seetharam, Bellur, Brookfield, WI, United States
Rose, Santanu, San Francisco, CA, United States
PATENT ASSIGNEE(S): MCW Research Foundation, Milwaukee, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6183733	B1	20010206
APPLICATION INFO.:	US 1998-9995		19980121 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Saucier, Sandra E.		
ASSISTANT EXAMINER:	Afremova, Vera		
LEGAL REPRESENTATIVE:	Quarles & Brady LLP		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	969		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for oral treatment of patients using different types of drugs that are not usually transported to circulation, if administered orally, is disclosed. Because the TC II-Cbl complex is stable to acid and proteolytic enzymes both outside and inside the intestinal absorptive cells, the method consists of oral administration of a drug bound to TC II-Cbl complex. In addition, the method can also be used for delivering Cbl to a large number of patients who do not absorb Cbl due to a variety of causes such as surgery of their stomach (ulcers) or of their terminal ileum (Crohn's disease).

L4 ANSWER 8 OF 68 USPATFULL
ACCESSION NUMBER: 2001:4509 USPATFULL
TITLE: ribB
INVENTOR(S): Black, Michael Terence, Chester Springs, PA, United States
Fedon, Jason Craig, Strafford, PA, United States
Hodgson, John Edward, Malvern, PA, United States
Knowles, David Justin Charles, Boroughbridge, United Kingdom
Lonetto, Michael Arthur, Collegeville, PA, United States
Kosmatka, Anna Lisa, Doylestown, PA, United States
Nicholas, Richard Oakley, Collegeville, PA, United States
Palmer, Leslie Marie, Audubon, PA, United States
Shilling, Lisa Kathleen, Newtown, PA, United States
Stodola, Robert King, Flourtown, PA, United States
Warren, Richard Lloyd, Blue Bell, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
SmithKline Beecham plc, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6171815	B1	20010109
APPLICATION INFO.:	US 1999-385898		19990830 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-971645, filed on 25 Nov 1997, now patented, Pat. No. US 6037728 Continuation of Ser. No. US 1997-911503, filed on 15 Aug 1997 Continuation of Ser. No. WO 1997-US14436, filed on 15 Aug 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-24022	19960816 (60)
DOCUMENT TYPE:	Patent	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Carlson, Karen Cochrane	
LEGAL REPRESENTATIVE:	Gimms, Edward R., Deibert, Thomas S., King, William T.	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1355	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides ribB **polypeptides** and polynucleotides encoding ribB **polypeptides** and methods for producing such **polypeptides** by recombinant techniques. Also provided are methods for utilizing ribB **polypeptides** to screen for antibacterial compounds.

L6 ANSWER 9 OF 68 USPATFULL
ACCESSION NUMBER: 2000:157392 USPATFULL
TITLE: Vitamin B.sub.12 derivatives and methods for their preparation
INVENTOR(S): Russell-Jones, Gregory J., New South Wales, Australia
McEwan, John F., New South Wales, Australia
PATENT ASSIGNEE(S): Biotech Australia Pty Limited, Roseville, Australia (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6152341		20001121
APPLICATION INFO.:	US 1999-310167		19990511 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1998-50050	19980612
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Wilson, James O.	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	760	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to methods for preparing vitamin B.sub.12 (VB.sub.12) derivatives suitable for linking to a polymer, nanoparticle or therapeutic agent, protein or peptide. The methods involve reacting the 5'OH group of VB.sub.12 or an analogue thereof with an active carbonyl electrophile and subsequently obtaining said VB.sub.12 derivatives. The invention also relates to novel VB.sub.12 derivatives, VB.sub.12 derivatives prepared by the methods of the present invention and uses thereof in the preparation of in the preparation of polymer complexes or nanoparticles.

L6 ANSWER 10 OF 68 USPATFULL
ACCESSION NUMBER: 2000:135190 USPATFULL
TITLE: pcrA protein from Streptococcus pneumoniae
INVENTOR(S): Black, Michael Terence, Chester Springs, PA, United States
Hodgson, John Edward, Malvern, PA, United States
Knowles, David Justin Charles, Redhill, United Kingdom
Lonetto, Michael Arthur, Collegeville, PA, United States
Nicholas, Richard O, Collegeville, PA, United States
Stedola, Robert King, Flourtown, PA, United States
Holmes, David J, West Chester, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6121414		20000919
APPLICATION INFO.:	US 1998-185825		19981104 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-885711, filed on 8 Jul 1997, now patented, Pat. No. US 5888718		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Duffy, Patricia A.		
LEGAL REPRESENTATIVE:	Gimmi, Edward R., Deibert, Thomas S., King, William T.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1638		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides pcrA polypeptides and DNA (RNA) encoding pcrA polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing pcrA polypeptides to screen for antibacterial compounds

L6 ANSWER 11 OF 68 USPATFULL
ACCESSION NUMBER: 2000:84267 USPATFULL
TITLE: Water soluble vitamin B.sub.12 receptor modulating agents and methods related thereto
INVENTOR(S): Morgan Jr., A. Charles, Mill Creek, WA, United States
Wilbur, D. Scott, Edmonds, WA, United States
Pathare, Pradyu M., Seattle, WA, United States
PATENT ASSIGNEE(S): The University of Washington, Seattle, WA, United States (U.S. corporation)
Receptagen Corporation, Edmonds, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6083926		20000704
APPLICATION INFO.:	US 1998 200422		19981123 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-561515, filed on 19 Oct 1995, now patented, Pat. No. US 5840712 which is a continuation-in-part of Ser. No. WO 1995-US6404, filed on 7 Apr 1995 which is a continuation-in-part of Ser. No. US 1995-406191, filed on 16 Mar 1995, now patented, Pat. No. US 5840880 which is a continuation-in-part of Ser. No. US 1995-406192, filed on 16 Mar 1995, now patented, Pat. No. US 5729287 And a continuation-in-part of Ser. No. US 1995-406194, filed on 16 Mar 1995, now patented, Pat. No. US 5869465 which is a continuation-in-part of Ser. No. US 1994-224831, filed on 8 Apr 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fonda, Kathleen K.		
LEGAL REPRESENTATIVE:	Seed Intellectual Property Law Group PLLC		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	28 Drawing Figure(s); 18 Drawing Page(s)		
LINE COUNT:	3274		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Vitamin B.sub.12 receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are disclosed. The vitamin B.sub.12 receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety linked by a water-solubilizing linker.

L6 ANSWER 12 OF 68 USPATFULL
ACCESSION NUMBER: 2000:80599 USPATFULL
TITLE: Nucleophilic polysubstituted aryl scridinium ester conjugates and synthesis thereof
INVENTOR(S): Law, Say-Jong, Westwood, MA, United States
PATENT ASSIGNEE(S): Bayer Corporation, East Walpole, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6080891		20000627
APPLICATION INFO.:	US 1997-920372		19970829 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-32947, filed on 17 Mar 1993, now patented, Pat. No. US 5663074 which is a continuation of Ser. No. US 1992-871601, filed on 17 Apr 1992, now patented, Pat. No. US 5241070 which is a continuation of Ser. No. US 1988-249620, filed on 26 Sep 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wortman, Donna		
ASSISTANT EXAMINER:	Brunsack, Brenda G.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 15 Drawing Page(s)		
LINE COUNT:	1138		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to novel nucleophilic polysubstituted aryl acridinium conjugates and the methods for preparation thereof. The novel
nucleophilic polysubstituted aryl acridinium conjugates are useful in biological assays, including novel assays for the determination of Vitamin B.sub.12, folate, cortisol, estradiol, and thromboxane B.sub.2.

L6 ANSWER 13 OF 68 USPATFULL
ACCESSION NUMBER: 2000:18241 USPATFULL
TITLE: Glucose Kinase from Streptococcus pneumoniae
INVENTOR(S): Black, Michael Terence, Chester Springs, PA, United States
Hodgson, John Edward, Malvern, PA, United States
Knowles, David Justin Charles, Redhill, United Kingdom
Lonetto, Michael Arthur, Collegeville, PA, United States
Nicholas, Richard O, Collegeville, PA, United States
Sisdols, Robert King, Flourtown, PA, United States
Burnham, Martin Karl Russel, Norristown, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. Corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6025179		20000215
APPLICATION INFO.:	US 1998-110910		19980706 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-896083, filed on 17 Jul 1997, now patented, Pat. No. US 5840560		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hoobie, Lisa J.
LEGAL REPRESENTATIVE: Gimmi, Edward R., King, William T., Deibert, Thomas S.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 1521
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides Glucose Kinase **polypeptides** and DNA (RNA) encoding Glucose Kinase **polypeptides** and methods for producing such **polypeptides** by recombinant techniques. Also provided are methods for utilizing Glucose Kinase **polypeptides** to screen for antibacterial compounds.

L6 ANSWER 14 OF 68 USPATFULL
ACCESSION NUMBER: 2000:9717 USPATFULL
TITLE: ribH
INVENTOR(S): Black, Michael Terence, Chester Springs, PA, United States
Fedon, Jason Craig, Strafford, PA, United States
Hodgson, John Edward, Malvern, PA, United States
Knowles, David Justin Charles, Sorcughbridge, United Kingdom
Kosmatka, Anna Lise, Doylestown, PA, United States
Nicholas, Richard Oakley, Collegeville, PA, United States
Palzer, Leslie Marie, Audubon, PA, United States
Shilling, Lisa Kathleen, Newtown, PA, United States
Sisdols, Robert King, Flourtown, PA, United States
Warren, Richard Lloyd, Blue Bell, PA, United States
Lonetto, Michael Arthur, Collegeville, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
SmithKline Beecham plc, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6017728		20000125
APPLICATION INFO.:	US 1997-978454		19971125 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996 24022	19960816 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Carlson, Karen Cochrane
LEGAL REPRESENTATIVE: Gimmi, Edward R., King, William T., Deibert, Thomas S.
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 1624
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides ribH **polypeptides** and polynucleotides encoding ribH **polypeptides** and methods for producing such **polypeptides** by recombinant techniques. Also provided are methods for utilizing ribH **polypeptides** to screen for antibacterial compounds.

L6 ANSWER 15 OF 68 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 2000442281 MEDLINE
DOCUMENT NUMBER: 20443608 PubMed ID: 10990201
TITLE: Oral absorption of **peptides** through the cobalamin (vitamin B12) pathway in the rat: mechanisms.
AUTHOR: Alsenz J; Russell-Jones G J; Westwood S; Levet Trafit B; de
CORPORATE SOURCE: Smadt P C
Preclinical Research Department, F. Hoffman-La Roche Ltd., Basle, Switzerland. jochen.alsenz@roche.com
SOURCE: PHARMACEUTICAL RESEARCH, (2000 Jul) 17 (7) 825-32.
Journal code: PHS. ISSN: 0724-8741.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200101
ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20010118
AB PURPOSE: This study was aimed at examining the extent and mechanism of uptake of cobalamin (Cbl) conjugated **peptides** in vitro and in vivo. METHODS: To enable acquisition of quantitative absorption data of Cbl-**peptides**, metabolically stable octapeptides (DP3), with (Cbl-Hex-DP3) or without a hexyl spacer (Cbl-DP3), were coupled to Cbl and **radiolabeled**. For comparison, LHRH coupled to Cbl was used as metabolically susceptible **peptide**. Biological recognition of Cbl-**peptides** was studied in the physiological order: binding by Intrinsic Factor (IF), recognition and transport of the IF complexes by IF-Cbl receptors (IFCR) on Caco-2 monolayers and oral absorption of the Cbl conjugates in the rat. RESULTS: All Cbl-**peptides** bound to IF and the IF-complexes were recognized by IFCR receptors on Caco-2 monolayers. Binding was saturable and could be inhibited by a 20-fold excess of IF-Cbl, but not of Non-intrinsic Factor (NIF)-Cbl. Oral administration of these ligands to rats resulted in absorption of 33%, 45%, 42%, and 31% of the applied **radioactivity** for Cbl, administration of a >3(5)-fold excess of unlabeled Cbl reduced uptake of all compounds to <4%. Tissue distribution and elimination of the metabolically stable Cbl-conjugates were comparable to Cbl. CONCLUSIONS: The endogenous Cbl uptake pathway can be exploited for oral **peptide** delivery as indicated by the specific and high (40-45%) uptake of metabolically stable Cbl-coupled octapeptides.

L6 ANSWER 16 OF 68 USPATFULL
ACCESSION NUMBER: 1999:170440 USPATFULL
TITLE: Cell culturing method and medium
INVENTOR(S): Curcio, Francesco, Pagnacco, Italy
Coon, Hayden G., East Sebago, ME, United States
Ambesi-Impiombato, F. Saverio, Udine, Italy
Liverotti L.L.C., East Sebago, ME, United States (U.S. corporation)
PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6008047		19991228
APPLICATION INFO.:	US 1993-44857		19980428 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-450022, filed on 7 Jun 1993, now patented, Pat. No. US 5888816 which is a continuation of Ser. No. US 1992-83772, filed on 30 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-44010, filed on 8 Apr 1993, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lankford, Jr., Leon B.
ASSISTANT EXAMINER: Tate, Christopher R.
LEGAL REPRESENTATIVE: Sundook Jr., John P.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 2990
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for producing an expanded non-transformed cell culture of human liver cells comprising the steps of: (1) preparing partially purified, minced human liver tissue, (2) concentrating the resulting cells and tissue pieces, (3) resuspending the concentrated tissue cells and pieces in a growth medium, (4) culturing the resuspended cells in the growth medium for a time and under conditions to effect substantial cell division, and (5) passaging the cultured human liver cells periodically to expand the culture. The growth medium comprises a combination of a basal medium and ingredients to provide a medium in which the cultured human liver cells are selectively proliferated without being transformed, provided an expanded culture of proliferated, functionally differentiated human liver cells that is substantially free of fibroblast, macrophage and capillary endothelial cells. Also provided is the improvement of harvesting cells of the expanded culture as a selected PDL preferably by, providing a high density cell suspension of such proliferated human liver cells, and incubating such high density cell suspension in a calm-down medium to induce a mitotically quiescent state and, using a culture procedure which encourages aggregation, making the cells adhere tightly to form a three-dimensional cell organization typical of the organ of origin, thereby forming organoids.

L6 ANSWER 17 OF 68 USPATFULL
ACCESSION NUMBER: 1999:142707 USPATFULL
TITLE: Clioquinol for the treatment of Alsheimer's disease
INVENTOR(S): Gerolymatos, Panayotis N., Kryoneri Attikis, Greece
P.N. Gerolymatos S.A., Kryoneri Attikis, Greece (non-U.S. corporation)

PATENT INFORMATION:	NUMBER	KIND	DATE
	US 6001852		19991214
APPLICATION INFO.:	US 1998-23544		19980213 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1997-IB983, filed on 8 Aug 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	GR 1996-960100286	19960813
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Criares, Theodore J.	
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	1176	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A new pharmaceutical composition is disclosed that comprises clioquinol, vitamin B.sub.12, and, optionally, pharmaceutical acceptable carriers and/or excipients. The use of the pharmaceutical composition removes or alleviates the side effects of clioquinol.

L6 ANSWER 18 OF 68 USPATFULL
ACCESSION NUMBER: 1999:155706 USPATFULL
TITLE: Pharmaceutical compositions comprising cliquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
INVENTOR(S): Gerolymatos, Panayotis N., Kryoneri Attikis, Greece
P.N. Gerolymatos S.A., Kryoneri Attikis, Greece (non-U.S. corporation)

PATENT INFORMATION:	NUMBER	KIND	DATE
	US 5994323		19991130
APPLICATION INFO.:	US 1998-23842		19980213 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	GR 1997-970100507	19971231
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Criares, Theodore J.	
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	1038	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical composition is disclosed that comprises cliquinol, vitamin B.sub.12, and, optionally, pharmaceutical acceptable carriers and/or excipients. The use of the pharmaceutical composition removes or alleviates the side effects of cliquinol.

L6 ANSWER 19 OF 68 USPATFULL
ACCESSION NUMBER: 1999:155699 USPATFULL
TITLE: Method of preparing polynucleotide carrier complexes for delivery to cells
INVENTOR(S): Iollo, Charles F., Encinitas, CA, United States
Mockler, Todd C., Carlsbad, CA, United States
Kwoh, Deborah Y., Carlsbad, CA, United States
PATENT ASSIGNEE(S): The Immune Response Corporation, Carlsbad, CA, United States (U.S. corporation)

PATENT INFORMATION:	NUMBER	KIND	DATE
	US 5994316		19991130
APPLICATION INFO.:	US 1996-604206		19960221 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Campbell, Bruce R.		
LEGAL REPRESENTATIVE:	Lahive & Cockfield, LLP, Remillard, Jane E		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 15 Drawing Page(s)		
LINE COUNT:	1587		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An improved method of forming substantially disperse and homogeneous polynucleotide carrier complexes is disclosed. The polynucleotide-carrier complexes can be administered in vivo to obtain significant levels and duration of gene expression

L6 ANSWER 20 OF 68 USPATFULL
ACCESSION NUMBER: 1999:89277 USPATFULL
TITLE: ribA
INVENTOR(S): Black, Michael Terence, Chester Springs, PA, United States
Fedon, Jason Craig, Strafford, PA, United States
Hodgson, John Edward, Malvern, PA, United States
Knowles, David Justin Charles, Borough/Wra>ge, United Kingdom
Lonetto, Michael Arthur, Collegeville, PA, United States
Komatka, Anna Lisa, Doylestown, PA, United States
Nicholas, Richard Oakley, Collegeville, PA, United States
Palmer, Leslie Marie, Audubon, PA, United States
Shilling, Lisa Kathleen, Newtown, PA, United States
Stodola, Robert King, Flourtown, PA, United States
Warren, Richard Lloyd, Blue Bell, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
SmithKline Beecham p.l.c., United Kingdom (non-U.S. corporation)

PATENT INFORMATION:	NUMBER	KIND	DATE
	US 5912701		19990803
APPLICATION INFO.:	US 1997-978458		19971125 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1997-US1436, filed on 15 Aug 1997 which is a continuation of Ser. No. US 1997-911503, filed on 15 Aug 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-24022	19960816 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Mannsfield, Nita	
LEGAL REPRESENTATIVE:	King, William T., Gimma, Edward R., Jackson, Arthur E.	
NUMBER OF CLAIMS:	1	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1736	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides ribA **polypeptides** and polynucleotides encoding ribA **polypeptides** and methods for producing such **polypeptides** by recombinant techniques. Also provided are methods for utilizing ribA **polypeptides** to screen for antibacterial compounds

L6 ANSWER 21 OF 68 USPATFULL
ACCESSION NUMBER: 1998:49216 USPATFULL
TITLE: Cell cultures of and cell culturing method for nontransformed pancreatic, thyroid, and parathyroid cells
INVENTOR(S): Coon, Hayden G., Gaithersburg, MD, United States
Ambesi-Impiombato, Francesco Saverio, Tricesimo, Italy
Curcio, Francesco, Pagnacco, Italy
PATENT ASSIGNEE(S): Human Cell Cultures Inc., East Sebago, ME, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5888816		19990330
APPLICATION INFO.:	US 1995-480022		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-83772, filed on 30 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-44010, filed on 8 Apr 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lankford, Jr., Leon B.		
ASSISTANT EXAMINER:	Tate, Christopher R.		
LEGAL REPRESENTATIVE:	Bundock, John F.		
NUMBER OF CLAIMS:	34		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	1992		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for producing an expanded, enriched, non-transformed human cell culture of human pancreatic, thyroid or parathyroid endocrine cells and other types of cells which comprises (1) preparing partially purified, minced tissue that includes a desired type of cells, (2) concentrating the desired cells, (3) resuspending the concentrated cells in a growth medium which selects in favor of the desired cells and in which those cells are proliferated without being transformed and differentiated functions are retained through periodic passaging, (4) culturing the resuspended cells in the growth medium to effect sustained cell division; and (5) passaging the cultured cells periodically to expand the culture. The present invention further provides clonal strains of cells derived from the above-mentioned cell culture and procedures to form matrix-embedded aggregated and non-aggregated cells for providing pseudotissues and products such as matrix-embedded pancreatic islets (pseudoislets). Growth medium and conditioned medium is provided for the culturing of the cells and clonal strains, the growth medium comprising a suitable basal medium supplemented with effective concentrations of hypothalamus and pituitary extracts, serum and other ingredients, which growth medium selects in favor of desired human cells and against passenger cells including fibroblast, macrophage, and capillary endothelial cells such that the desired cells are selectively proliferated without being transformed and an expanded cell culture is provided of functionally differentiated, expanded, non-transformed human cells that is substantially free of such passenger cells.

L6 ANSWER 21 OF 68 USPATFULL (Continued)

L6 ANSWER 22 OF 68 USPATFULL
ACCESSION NUMBER: 1999:36952 USPATFULL
TITLE: Methods for the detection of nitric oxide in fluid media
INVENTOR(S): Lee, Ching-San, Encinitas, CA, United States
PATENT ASSIGNEE(S): Medtox, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5885843		19990323
APPLICATION INFO.:	US 1996-745678		19961108 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Green, Lora M.		
ASSISTANT EXAMINER:	Ricciardano, Joseph W.		
LEGAL REPRESENTATIVE:	Gray Cary Ware & Freidenrich, Reiter, Stephen E.		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	907		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Non-invasive methods have been developed for the measurement of NO levels in a variety of fluid media, e.g., body fluids. The present invention embraces the use of a semi-permeable vessel wherein said vessel contains an NO reacting substance to trap NO diffusing therein, and a simple physical or chemical detection method to measure the levels of the end products. Since NO is a neutral gas molecule, it is capable of diffusing freely across a wide range of biocompatible polymer membranes which exhibit a high permeability to NO and other neutral gas molecules, such as O.sub.2 and CO.sub.2, which are not permeable to charged molecules, such as NO.sub.3.sup.- or NO.sub.2.sup.-. The latter two compounds are ubiquitously present in body fluids and often interfere with the measurement of NO levels. The permeability of selected membranes to NO, but not to NO.sub.3.sup.- or NO.sub.2.sup.-, makes it possible for the bage employed in the practice of the invention to selectively collect NO, even in the presence of potentially competing species. The simple, easy and non-invasive methods of the invention will find a variety of uses, e.g., for diagnosis and monitoring of NO overproduction (and underproduction) that has been associated with many inflammatory and infectious diseases.

L6 ANSWER 23 OF 68 USPATFULL
ACCESSION NUMBER: 1999:19129 USPATFULL
TITLE: Methods of receptor modulation and uses therefor
INVENTOR(S): Morgan, Jr., A. Charles, Edmonds, WA, United States
Wilbur, D. Scott, Edmonds, WA, United States
PATENT ASSIGNEE(S): Receptagen Corporation, Edmonds, WA, United States (U.S. corporation)
University of Washington, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5869465		19990209
APPLICATION INFO.:	US 1995-406196		19950316 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-224831, filed on 8 Apr 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Tsang, Cecilia J.		
ASSISTANT EXAMINER:	Gupta, Anish		
LEGAL REPRESENTATIVE:	Christensen O'Connor Johnson & Kindness PLLC		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	28 Drawing Figure(s); 18 Drawing Page(s)		
LINE COUNT:	2882		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are utilized for the treatment and diagnosis of a variety of disorders in warm-blooded animals, including neoplastic disorders. The receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety.

L6 ANSWER 24 OF 68 USPATFULL
ACCESSION NUMBER: 1999:4361 USPATFULL
TITLE: PCR A
INVENTOR(S): Black, Michael Terence, Chester Springs, PA, United States
Hudgson, John Edward, Malvern, PA, United States
Knowles, David Justin Charles, Redhill, United Kingdom
Lonsetz, Michael Arthur, Collegeville, PA, United States
O Nicholas, Richard, Collegeville, PA, United States
Stodola, Robert King, Flourtown, PA, United States
Holmes, David J., West Chester, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5858718		19990112
APPLICATION INFO.:	US 1997-889711		19970708 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Duffy, Patricia		
LEGAL REPRESENTATIVE:	Gimmi, Edward R., King, William T., Jackson, Arthur E.		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1352		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides pcrA **polypeptides** and DNA (RNA) encoding pcrA **polypeptides** and methods for producing such **polypeptides** by recombinant techniques. Also provided are methods for utilizing pcrA **polypeptides** to screen for antibacterial compounds.

L6 ANSWER 25 OF 68 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 2
ACCESSION NUMBER: 1994:207260 CAPLUS
DOCUMENT NUMBER: 120:275101
TITLE: Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
INVENTOR(S): Unger, Evan C.; Matsunaga, Terry O.; Yellowhair, David
PATENT ASSIGNEE(S): Imarx Pharmaceutical Corp., USA
SOURCE: U.S., 40 pp. Cont.-in-part of U.S. Ser. No. 307,305.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 19
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5733572	A	19980331	US 1994-346424	19941129
US 5088499	A	19920218	US 1990-569838	19900820
WO 9109639	A1	19910711	WO 1990-US7500	19901219
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
JP 05502475	T2	19930513	JP 1991-502276	19901219
AT 180170	E	19990615	AT 1991-902857	19901219
ES 2131053	T3	19990716	ES 1991-902857	19901219
US 5328466	A	19940712	US 1991-717064	19910618
WO 9232247	A1	19921223	WO 1992-US2615	19920331
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
AU 9220020	A1	19930112	AU 1992-20020	19920331
AU 667471	B2	19960328		
JP 06508164	T2	19940922	JP 1992-508847	19920331
EP 616508	A1	19940928	EP 1992-912456	19920331
EP 616508	B1	20010718		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
AT 203146	E	20010815	AT 1992-912456	19920331
US 5469854	A	19951128	US 1993-74339	19930611
US 5580575	A	19961203	US 1993-76250	19930611
US 5348016	A	19940920	US 1993-88268	19930707
US 5542935	A	19960806	US 1993-160232	19931130
US 5558118	A	19961217	US 1993-159687	19931130
US 5769080	A	19980623	US 1994-199432	19940222
WO 9428874	A1	19941222	WO 1994-US5613	19940519
W: AU, CA, CN, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5773024	A	19980630	US 1994-307305	19940916
CA 2177713	AA	19950608	CA 1994-2177713	19941130
JP 09506098	T2	19970617	JP 1994-515763	19941130
US 5571497	A	19961105	US 1995-468056	19950606
CN 1140310	A	19980429	CN 1996-193069	19960327
US 6003329	A	19991214	US 1996-645719	19960618
US 5935553	A	19990810	US 1996-758179	19961125
US 5985246	A	19991116	US 1997-888426	19970708
AU 711327	B2	19991125	AU 1998-56271	19980224
AU 9856271	A1	19980827		
AU 9868405	A1	19981203	AU 1998-68405	19981012
AU 731075	B2	20010329		

L6 ANSWER 25 OF 68 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 2 (Continued)

AU 9910042	A1	19990304	AU 1999-10043 19990104
PRIORITY APPLN. INFO.:			US 1989-457079 B2 19891222
			US 1990-569838 A2 19900820
			US 1991-717699 B2 19910618
			US 1991-717064 A2 19910618
			US 1993-76329 A2 19930611
			US 1993-76250 A2 19930611
			US 1993-159674 B2 19931130
			US 1993-159687 A2 19931130
			US 1993-160232 A2 19931130
			US 1994-307305 A2 19940916
			WO 1990-US7500 W 19901219
			US 1991-759377 A3 19910826
			US 1992-810609 A3 19921208
			WO 1992-US2615 A 19920331
			US 1992-967974 A2 19921027
			US 1993-17602 A3 19930212
			US 1993-18112 RN 19930217
			US 1993-85608 A3 19930630
			US 1993-88268 A3 19930707
			US 1993-109305 A 19931130
			US 1993-163039 A3 19931206
			US 1994-210853 EP 19940311
			AU 1994-70416 A1 19940819
			US 1994-346424 19941129
			AU 1995-21650 A3 19941130
			WO 1994-US13417 W 19941130
			US 1995-395483 A3 19950228
			US 1995-468056 A3 19950606
			US 1995-471250 A3 19950606
			US 1996-645719 A3 19960618

AB Gas and gaseous precursor filled microspheres, and foams provide novel topical and s.c. delivery vehicles for various active ingredients, including drugs and cosmetics. Gas and gaseous precursor filled microdispersions were prepd. from dipalmitoylphosphatidylcholine

L6 ANSWER 26 OF 68 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1998:55494 CAPLUS
DOCUMENT NUMBER: 128:112664
TITLE: Pressure-mediated binding of biomolecular complexes
INVENTOR(S): Litt, Gerald J.; Laughern, James A., Jr.; Green, J., Hess, Robert A.; Paulus, Henry
PATENT ASSIGNEE(S): Bioseq, Inc., USA; Litt, Gerald J.; Laughern, James A., Jr.; Green, David J., Hess, Robert A.; Paulus, Henry
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9800322	A1	19980108	WO 1997-US1198	19970701
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2253218	AA	19980108	CA 1997-2253218	19970701
AU 9736437	A1	19980121	AU 1997-36437	19970701
EP 924991	A1	19990630	EP 1997-933189	19970701
EP 924991	B1	20011004		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:			US 1996-20562 P	19960702
			US 1997-44595 P	19970422
			WO 1997-US1198 W	19970701

AB The invention relates to (1) pressure-mediated dissocn. of an analyte complexed with an endogenous binding partner to enable detection of a complex formed from the analyte and an exogenous binding factor, (2) pressure-mediated assocn. of an analyte and an exogenous binding partner to enable more rapid and/or more sensitive detection of an analyte, and (3) pressure-mediated assocn. and dissocn. of biomol. complexes to enable improve assays by dissocg. endogenous analyte complexes and improving assay speed and sensitivity by assocg. the analyte mols. with exogenously supplied binding partners. Pressure can also be used to improve the sepn. of compds. from contaminated mixts.

L6 ANSWER 27 OF 68 USPATFULL
ACCESSION NUMBER: 1998:157191 USPATFULL
TITLE: Cell cultures of and cells culturing method for nontransformed parotid cells
INVENTOR(S): Coon, Hayden G., Gaithersburg, MD, United States
Ambesi-Impiombato, Francesco Saverio, Tricesimo, Italy
Curcio, Francesco, Pagnacco, Italy
PATENT ASSIGNEE(S): Human Cell Cultures Inc., East Sebago, ME, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843584		19981215
APPLICATION INFO.:	US 1995-486550		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-83772, filed on 30 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-44010, filed on 8 Apr 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lankford, Jr., Leon B		
ASSISTANT EXAMINER:	Tate, Christopher R		
LEGAL REPRESENTATIVE:	Sundock, John P.		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	1832		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for producing an expanded non-transformed cell culture comprising the steps of: (1) preparing partially purified, minced tissue; (2) concentrating the resulting cells and tissue pieces; (3) resuspending the concentrated tissue cells and pieces in a culture medium capable of supporting sustained cell division that is contained in a culture vessel; (4) incubating the cells; and (5) passaging the cells periodically. The present invention further provides clonal strains of cells derived from the above-mentioned cell culture, medium and conditioned medium designed for the culturing of parotid cells and other glandular cells such as pancreatic, thyroid, and parathyroid, and cells, and the use of cultured pancreatic cells to form pancreatic pseudotissues composed of matrix-embedded aggregated (pseudoacinar) or individual cells, to treat blood sugar disorders in mammals, and to test for cytotoxicity and autoimmune activities with reference to pancreatic endocrine cells. The nontransformed cells are cultured in a growth medium comprising a suitable basal medium supplemented with effective concentrations of hypothalamus and pituitary extracts, and serum.

L6 ANSWER 28 OF 68 USPATFULL
ACCESSION NUMBER: 1998:147590 USPATFULL
TITLE: Receptor modulating agents
INVENTOR(S): Morgan, Jr., A. Charles, Edmonds, WA, United States
Wilbur, D. Scott, Edmonds, WA, United States
Receptagen Corporation, Edmonds, WA, United States (U.S. corporation)
PATENT ASSIGNEE(S): University of Washington, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5840880		19981124
APPLICATION INFO.:	US 1995-406191		19950316 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-224831, filed on 8 Apr 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Robinson, Douglas		
ASSISTANT EXAMINER:	Gupta, Anish		
LEGAL REPRESENTATIVE:	Christensen O'Connor Johnson & Kindness PLLC		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	26 Drawing Figure(s); 20 Drawing Page(s)		
LINE COUNT:	2940		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway. The modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety.

L6 ANSWER 29 OF 68 USPATFULL
ACCESSION NUMBER: 1998:147427 USPATFULL
TITLE: Water soluble vitamin B.sub.12 receptor modulating agents and methods related thereto
INVENTOR(S): Morgan, Jr., A. Charles, Mill Creek, WA, United States
Wilbur, D. Scott, Edmonds, WA, United States
Pathare, Pradip M., Seattle, WA, United States
PATENT ASSIGNEE(S): Receptagen Corporation, Edmonds, WA, United States (U.S. corporation)
University of WA, Edmonds, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5840712		19981124
APPLICATION INFO.:	US 1995-545181		19951019 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-406191, filed on 16 Mar 1995 Ser. No. Ser. No. US 1995-406192, filed on 16 Mar 1995, now patented, Pat. No. US 5703287 And Ser. No. US 1995-406194, filed on 16 Mar 1995 , each Ser. No. US which is a continuation-in part of Ser. No. US 1994-224831, filed on 8 Apr 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Nutzell, Paula K.		
ASSISTANT EXAMINER:	Bekerlyar, Heather A		
LEGAL REPRESENTATIVE:	Christensen O'Connor Johnson & Kindness PLLC		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	28 Drawing Figure(s); 18 Drawing Page(s)		
LINE COUNT:	3615		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Vitamin B.sub.12 receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are disclosed. The vitamin B.sub.12 receptor modulating agents moiety linked by a water-solubilizing linker.

L6 ANSWER 30 OF 68 USPATFULL
ACCESSION NUMBER: 1998:82596 USPATFULL
TITLE: Method of altering blood sugar levels using non-transformed human pancreatic cells that have been expanded in culture
INVENTOR(S): Coon, Hayden G., Gaithersburg, MD, United States
Ambesi-Impiombato, Francesco Saverio, Tricesimo, Italy
Curcio, Francesco, Pagnacco, Italy
PATENT ASSIGNEE(S): Human Cell Cultures Inc., East Sebago, ME, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5780299		19980714
APPLICATION INFO.:	US 1995-480037		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-83772, filed on 30 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-44010, filed on 8 Apr 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lankford, Jr., Leon B.		
ASSISTANT EXAMINER:	Tate, Christopher R		
LEGAL REPRESENTATIVE:	Sundock, John P.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	1828		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for producing an expanded non-transformed cell culture comprising the steps of: (1) preparing partially purified, minced tissue; (2) concentrating the resulting cells and tissue pieces; (3) resuspending the concentrated tissue cells and pieces in a culture medium capable of supporting sustained cell division that is contained in a culture vessel; (4) incubating the cells; and (5) passaging the cells periodically. The present invention further provides clonal strains of cells derived from the above-mentioned cell culture, medium and conditioned medium designed for the culturing of such cells, including pancreatic, thyroid, parathyroid, and parotid cells, and the use of cultured pancreatic cells to form pancreatic pseudotissues composed of matrix-embedded aggregated (pseudoacinar) or individual cells, to treat blood sugar disorders in mammals, and to test for cytotoxicity and autoimmune activities with reference to pancreatic endocrine cells.

L6 ANSWER 31 OF 68 USPATFULL
ACCESSION NUMBER: 1998:39675 USPATFULL
TITLE: Biotinylated cobalamins
INVENTOR(S): Wilbur, D. Scott, Edmonds, WA, United States
Pathare, Pradip M., Seattle, WA, United States
Morgan, Jr., A. Charles, Camino Island, WA, United States
PATENT ASSIGNEE(S): University of Washington, Seattle, WA, United States (U.S. corporation)
Receptagen Corp., Edmonds, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5719287		19980214
APPLICATION INFO.:	US 1995-406192		19950316 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-224831, filed on 8 Apr 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kunz, Jeffrey E.		
LEGAL REPRESENTATIVE:	Christensen O'Connor Johnson & Kindness PLLC		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 18 Drawing Page(s)		
LINE COUNT:	3099		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A biotinylated cobalamin, formed from a vitamin B.sub.12 molecule coupled to a biotin molecule, is disclosed. In a preferred embodiment, the vitamin B.sub.12 molecule is cyanocobalamin. The biotin molecule can also be coupled to a rerouting moiety, optionally through a biotin binding protein such as avidin or streptavidin. The biotinylated cobalamin binds to a cell surface receptor, is invaginated, and once internalized affects the receptor trafficking pathway.

L6 ANSWER 32 OF 68 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 1998341676 EMBASE
TITLE: Transmethylation reactions and autoradiographic distribution of vitamin B12: Effects of clioquinol treatment in mice.
AUTHOR: Yassin M.S.; Ekblom J.; Lofberg C.; Oreland L.
CORPORATE SOURCE: L. Oreland, Dept. of Neuroscience (Pharmacology), Biomedical Center, Uppsala University, Box 593, S-751 24 Uppsala, Sweden
SOURCE: Japanese Journal of Pharmacology, (1998) 78/1 (55-61). Refs: 23
ISSN: 0021-5198 CODEN: JJPAAZ
COUNTRY: Japan
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 010 Pharmacology
037 Drug Literature Index
052 Toxicology
LANGUAGE: English
SUMMARY LANGUAGE: English
AB The catastrophic epidemic of subacute myelo-optic neuropathy (SMON) affected Japan around 1970 with thousands of victims. The cause was attributed to high doses of locally acting oxyquinolines. It has been speculated that oxyquinoline derivatives of the clioquinol type can disturb the retention of vitamin B12 through chelation of Co2+. In the present paper, possible effects of clioquinol on the uptake and tissue distribution of [57Co]-cyanocobalamin have been studied in mice. In vivo experiments showed markedly decreased accumulation of radiolabelled vitamin B12 in the kidney and skin in animals that were pre-treated with clioquinol. The chloroform:water partition coefficients for [57Co]-cyanocobalamin in the presence or absence of clioquinol were also determined. No statistically significant alterations in the partition coefficient for [57Co]-cyanocobalamin in the presence of clioquinol was evident, indicating that clioquinol does not bind cobalt. In addition, transmethylation reactions in the CNS in mice treated with clioquinol were studied. Specific activities of methionine adenosyltransferase, and S-adenosylhomocysteine levels were not affected. In contrast, clioquinol treatment caused a significant increase in the levels of S-adenosylmethionine in the brain. The data of the present study show that clioquinol treatment can affect the accumulation of vitamin B12 in the kidney and the skin but not in the brain. These results do not support the hypothesis that clioquinol causes its damage to the nervous system by a direct chemical interaction with vitamin B12.

L6 ANSWER 33 OF 68 USPATFULL
ACCESSION NUMBER: 97:106797 USPATFULL
TITLE: Anti-receptor and growth blocking antibodies to the vitamin B.sub.12 /transcobalamin II receptor and binding sites
INVENTOR(S): Morgan, Jr., Allon Charles, Edmonds, WA, United States
PATENT ASSIGNEE(S): Receptagen Corporation, Edmonds, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5686504		19971118
APPLICATION INFO.:	US 1994-306504		19940913 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-880540, filed on 8 May 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wucker, Christine M.		
ASSISTANT EXAMINER:	Stucker, Jeffrey		
LEGAL REPRESENTATIVE:	Seed and Berry LLP		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	1860		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There is disclosed anti-receptor and growth blocking agents to the vitamin B.sub.12 /transcobalamin II receptor and binding sites. The anti-receptor and growth blocking agents antagonize or modulate the cellular depletion of vitamin B.sub.12, thus preventing or inhibiting cell division or causing apoptosis. Anti-receptor and growth blocking agents of the present invention include proteins (such as antibodies and antibody derivatives), peptides and small organic molecules. In a preferred embodiment, the anti-receptor agent is an antibody to the vitamin B.sub.12 /transcobalamin II receptor.

L6 ANSWER 34 OF 68 USPATFULL
ACCESSION NUMBER: 97:91199 USPATFULL
TITLE: Nanoparticles containing an active substance and a ketalized polytartramidic acid, process for their preparation, and use thereof
INVENTOR(S): Ahlers, Michael, Mainz, Germany, Federal Republic of
Welch, Axel, Frankfurt am Main, Germany, Federal Republic of
Reipke, Gerhard, Hofheim, Germany, Federal Republic of
Russell-Jones, Gregory, Middel Cove, Australia
PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5676931		19971007
APPLICATION INFO.:	US 1995-399474		19950307 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1994-4407896	19940309
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Spear, James M.	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	571	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Nanoparticles containing an active substance and a ketalized polytartramidic acid, process for their preparation, and use thereof. Nanoparticles containing an active substance and a ketalized polytartramidic acid are suitable as vehicles for active substances, in particular for peptides and proteins. Processes for the preparation of the nanoparticles are described.

L4 ANSWER 35 OF 68 USPATFULL
ACCESSION NUMBER: 97:81974 USPATFULL
TITLE: Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
INVENTOR(S): Shapiro, Howard K., 214 Price Ave. PJ2, Narberth, PA, United States 19072

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5668117		19970916
APPLICATION INFO.:	US 1993-32203		19930629 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-26617, filed on 23 Feb 1993, now abandoned which is a continuation of Ser. No. US 1991-660561, filed on 22 Feb 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kight, John		
ASSISTANT EXAMINER:	Lewis, Louise		
LEGAL REPRESENTATIVE:	Perrella, O. J.		
NUMBER OF CLAIMS:	29		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1963		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Therapeutic compositions comprising an effective amount of at least one carbonyl trapping agent alone or in combination with a therapeutically effective of a co-agent or medicament are disclosed. The compositions are used to treat a mammal suffering from a neurological disease characterized by covalent bond crosslinking between the nerve cells, other cellular structures and their intracellular and extracellular components, with disease induced carbonyl-containing aliphatic or aromatic hydrocarbons present in mammals.

L4 ANSWER 36 OF 68 USPATFULL
ACCESSION NUMBER: 97:78345 USPATFULL
TITLE: Nucleophilic polysubstituted aryl acridinium ester conjugates and syntheses thereof
INVENTOR(S): Law, Say-Jong, Westwood, MA, United States
PATENT ASSIGNEE(S): Chiron Diagnostics Corporation, Walpole, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5663074		19970902
APPLICATION INFO.:	US 1993-33947		19930317 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-871601, filed on 17 Apr 1992 which is a continuation of Ser. No. US 1988-249620, filed on 26 Sep 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Woodward, Michael P.		
LEGAL REPRESENTATIVE:	Morgenstern, Arthur S., Blackburn, Robert P., Klee, Maurice M.		
NUMBER OF CLAIMS:	63		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 15 Drawing Page(s)		
LINE COUNT:	1854		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to novel nucleophilic polysubstituted aryl acridinium conjugates and the methods for preparation thereof. The novel
nucleophilic polysubstituted aryl acridinium conjugates are useful in biological assays, including novel assays for the determination of Vitamin B.sub.12, folate, cortisol, estradiol, and thromboxane B.sub.2.

L4 ANSWER 37 OF 68 USPATFULL
ACCESSION NUMBER: 97:59097 USPATFULL
TITLE: Method for preparing an expanded culture and clonal strains of pancreatic, thyroid or parathyroid cells
INVENTOR(S): Coon, Hayden G., Gaithersburg, MD, United States
Asbasi-Tejiondato, Francesco Saverio, Tricesimo, Italy
Curcio, Francesco, Pagnacco, Italy
PATENT ASSIGNEE(S): Human Cell Cultures, Inc., Gaithersburg, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5646025		19970708
APPLICATION INFO.:	US 1993-480149		19950607 (5)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-81772, filed on 30 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-44010, filed on 8 Apr 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rollins, John W.		
ASSISTANT EXAMINER:	Larson, Kristin		
LEGAL REPRESENTATIVE:	Leydig, Voit & Mayer, Ltd.		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Figure(s), 11 Drawing Page(s)		
LINE COUNT:	1831		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for producing an expanded non-transformed cell culture comprising the steps of: (1) preparing partially purified, minced tissue, (2) concentrating the resulting cells
and tissue pieces, (3) resuspending the concentrated tissue cells and pieces in a culture medium capable of supporting sustained cell division
that is contained on a culture vessel, (4) incubating the cells; and (5)
passaging the cells periodically. The present invention further provides
clonal strains of cells derived from the above-mentioned cell culture, medium and conditioned medium designed for the culturing of such cells, including pancreatic, thyroid, parathyroid, and parotid cells, and the use of cultured pancreatic cells to form pancreatic pseudoacinus composed of matrix-embedded aggregated (pseudoalveta) or individual cells, to treat blood sugar disorders in mammals, and to test for cytotoxicity and autoimmune activities with reference to pancreatic endocrine cells.

L4 ANSWER 38 OF 68 MEDLINE
ACCESSION NUMBER: 1998012901 MEDLINE
DOCUMENT NUMBER: 98012901 PubMed ID: 9352652
TITLE: Apical expression of functional sialoglycoprotein receptor
in the human intestinal cell line HT-29.
AUTHOR: Mu J S, Gordon M, Shao J S, Alpers D H
CORPORATE SOURCE: Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA.
CONTRACT NUMBER: DK-01-31487
SOURCE: GASTROENTEROLOGY, (1997 Nov) 113 (5) 1501-9.
Journal code: FNS; 0374630. ISSN: 0016-5085.
PUB. COUNTRY: United States
LANGUAGE: Journal; Article; (JOURNAL ARTICLE)
FILE SEGMENT: English
ENTRY MONTH: Abridged Index Medicus Journals, Priority Journals
ENTRY DATE: 199711
Entered STN: 19971224
Last Updated on STN: 19971224
Entered Medline: 19971113

AB BACKGROUND & AIMS: The sialoglycoprotein receptor localizes to the basolateral membrane of hepatocytes and to the apical membrane of enterocytes. The aim of this study was to examine HT-29 cells as a polarized cell model for studying apically localized endogenous asialoglycoprotein receptor. METHODS: Subunits H1 and H2 (human) were detected by Western blot and immunoprecipitated using subunit-specific antisera against hepatic receptor peptides. Receptor function was assessed by uptake of iodinated asialo-orosomucoid, immunoglobulin (Ig) A1, and haptocorrin. Immunocytochemistry was analysed by standard light and confocal microscopy. RESULTS: Receptor content of the minor subunit, H2, was predominant. HT-29 cells mediated specific uptake and degradation of 125I asialo-orosomucoid. A high-affinity (0.6 x 10(-9) mmol/l) and a low-affinity binding site were present. The specific ligand binding capacity of the apical surface was approximately twice that of the basolateral surface. Immunocytochemistry revealed a predominant apical membrane location of the minor receptor subunit, with some intracellular receptor. The apical H2 subunit was preferentially labelled with amino acid precursors as compared with basolaterally located subunit. Human IgA1 bound specifically to HT-29 cells with a molar ratio of 0.26 compared with asialo-orosomucoid, porcine
haptocorrin bound with a molar ratio of 1.35. CONCLUSIONS: HT-29 cells produce a functional apically located asialoglycoprotein receptor and provide a model for receptor trafficking in the enterocyte.

L6 ANSWER 39 OF 68 USPATFULL
ACCESSION NUMBER: 96:99222 USPATFULL
TITLE: Combination medications containing alpha-lipoic acid and related
INVENTOR(S): Weischer, Carl-Heinrich, Bonn, Germany, Federal Republic of
Ulrich, Heinz, Niedernberg, Germany, Federal Republic of
Wessel, Klaus, Frankfurt, Germany, Federal Republic of
PATENT ASSIGNEE(S): Asta Medica Aktiengesellschaft, Dresden, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5569670		19961029
APPLICATION INFO.:	US 1995 404153		19950314 (5)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-197643, filed on 16 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-71359, filed on 4 Jun 1993, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1992-4218573	19920605
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Dees, Jos e G.	
ASSISTANT EXAMINER:	Lendvai, Deborah	
LEGAL REPRESENTATIVE:	Cushman Darby & Cushman, LLP	
NUMBER OF CLAIMS:	1	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1013	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical composition containing alpha-lipoic acid, dihydrolipoic acid, metabolites of alpha-lipoic acid (inter alia bisnortetralipoic acid and tetranorlipoic acid), optical isomers R- and S- forms of alpha-lipoic acid in oxidized and reduced form together with a vitamin, especially vitamins A, B1, B2, B6, B12, C and E and their pharmaceutically acceptable salts. The compositions are useful for producing analgesic, anti-inflammatory, antidiabetic, cytoprotective, anti-ulcer, antinecrotic, neuroprotective, detoxifying, anti-ischemic, liver function regulating, anti-allergic, immune-stimulating and anticarcinogenic effects.

L6 ANSWER 40 OF 68 USPATFULL
ACCESSION NUMBER: 96:65493 USPATFULL
TITLE: Nucleophilic polysubstituted aryl acridinium ester conjugates uses thereof
INVENTOR(S): Law, Say-Jong, Westwood, MA, United States
Chang, Steve C. S., Franklin, MA, United States
Klukas, Carol K., Pittsburgh, PA, United States
Vitkus=kas, Christine A., North Attleboro, MA, United States
PATENT ASSIGNEE(S): Ciba Corning Diagnostics Corp., Medfield, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5521801		19960723
APPLICATION INFO.:	US 1994-292946		19940818 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-32085, filed on 17 Mar 1993, now abandoned which is a division of Ser. No. US 1992-871601, filed on 17 Apr 1992, now patented, Pat. No. US 5241070, issued on 13 Aug 1993 which is a continuation of Ser. No. US 1988-249620, filed on 26 Sep 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Spiegel, Carol A.		
LEGAL REPRESENTATIVE:	Morgenstern, Arthur S., Roesler, Judith A		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 15 Drawing Page(s)		
LINE COUNT:	1444		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to the novel assay methods utilizing nucleophilic polysubstituted aryl acridinium ester conjugates as the tracers. Conjugates prepared by covalent coupling of novel nucleophilic polysubstituted aryl acridinium esters with biological compounds including small organic molecules such as Vitamin B12, folate, cortisol, estradiol, and thromboxane B2, were found useful in the development of highly sensitive assays for the analytes of diagnostic interest.

L6 ANSWER 41 OF 68 USPATFULL
ACCESSION NUMBER: 95:64857 USPATFULL
TITLE: Folate immunoassay utilizing folate binding protein in a multictional antibody format
INVENTOR(S): Beggs, Michael J., Waukegan, IL, United States
Sohn, Linda J., Palatine, IL, United States
Herrmann, Robert J., Gurnee, IL, United States
Heu, Stephen, Vernon Hills, IL, United States
Hawkesworth, David J., Mundelein, IL, United States
Pinkus, Mary S., Chicago, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5434087		19950718
APPLICATION INFO.:	US 1993-21942		19930224 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Scheiner, Toni R		
ASSISTANT EXAMINER:	Parsons, Nancy J.		
LEGAL REPRESENTATIVE:	Weinstein, David L.		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s), 2 Drawing Page(s)		
LINE COUNT:	711		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An improved method for performing immunoassays whereby specific binding proteins for vitamin B12, folate and other target analytes are utilized with antibodies with different specificities for the binding proteins. Antibodies bridge the specific binding protein directly or indirectly to a capturable material.

L6 ANSWER 42 OF 68 BIOSIS COPYRIGHT 2001 BIOSIS
ACCESSION NUMBER: 1995:509032 BIOSIS
DOCUMENT NUMBER: PREV199548114082
TITLE: Inhibition of chondrocyte cathepsin B and L activities by insulin-like growth factor-II (IGF-II) and its Ser-29 variant in vitro: Possible role of the mannose 6-phosphate/IGF-II receptor.
AUTHOR(S): De Caunnick, F., Fouraudeau, S., Pegano, M., Tamgrie, L.; Blanchard, D., Wallegut, J., Corvol, M. (1)
CORPORATE SOURCE: (1) Institut National de la Sante et de la Recherche Medicale, U 30, 149 rue de Sevres, 75743 Paris, Cedex 15 France
SOURCE: Molecular and Cellular Endocrinology, (1995) Vol. 113, No. 2, pp. 205-213.
ISSN: 0303-7207.
DOCUMENT TYPE: Article
LANGUAGE: English
AB Lysosomal enzymes and IGF-II both bind to the mannose 6-phosphate (M6P)/IGF-II receptor. This receptor targets newly synthesized lysosomal enzymes to lysosomes. The functional meaning of IGF-II binding to this receptor is not well known. We have postulated that IGF-II may affect the targeting of lysosomal enzymes in cartilage remodeling. We therefore examined the effect of IGF-II, the Ser-29 IGF-II variant (V1GF-II) and IGF-I on lysosomal cathepsin B and L activities from post-natal rabbit chondrocytes in vitro. This effect was compared with the ability of each peptide to stimulate chondrocyte-sulfated proteoglycan synthesis. The sulfating dose-response relationship of the IGF peptides corresponded to their relative binding affinities for the type I IGF receptor (IGF-I gt IGF-II gt V1GF-II). The intracellular cathepsin B and L activities were inhibited in a time- and dose-dependent manner by IGF-II or V1GF-II. Maximal inhibition of cathepsin B and L activities (40 and 30% below controls, respectively) was found after an 8 h treatment with 100 ng/ml IGF-II or V1GF-II. By contrast, IGF-I up to 1 mu-g/ml or insulin up to 2 mu-g/ml had no inhibitory effect. The relative potency pattern corresponded to the binding profile of each ligand for the M6P/IGF-II receptor. A treatment of chondrocytes with IGF-I or insulin had no significant effect on the binding of radiolabelled IGF-II at the cell surface up to 120% of controls, whereas IGF-II or V1GF-II had no such effect. Thus, it is unlikely that the inhibition of lysosomal enzyme activities by IGF-II peptides could result from a redistribution of M6P/IGF-II receptors from intracellular compartments to the plasma membrane. We hypothesize that internalized IGF-II peptides could occupy the intracellular M6P/IGF-II binding sites required for the targeting of cathepsins B and L to lysosomes.

L6 ANSWER 43 OF 68 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1994:442743 CAPLUS
DOCUMENT NUMBER: 121:42743
TITLE: Microparticle formulations containing biodegradable mixed polymers
INVENTOR(S): Fritzsch, Thomas; Heldmann, Dieter; Wertschieg, Werner
PATENT ASSIGNEE(S): Schering A.-G., Germany
SOURCE: Ger. Offen., 6 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4232755	A1	19940331	DE 1992-4232755	19920926
WO 9407519	A1	19940414	WO 1993-EP2432	19930908
W: AU, CA, FI, HU, JP, KR, NO, NZ, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 662005	A1	19950712	EP 1993-919293	19930908
EP 662005	B1	19980429		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
HU 71683	A2	19960129	HU 1995-876	19930908
JP 08504198	T2	19960514	JP 1993-508630	19930908
AU 687360	B2	19980226	AU 1993-49592	19930908
AT 165517	E	19980515	AT 1993-919293	19930908
ES 2118251	T3	19980916	ES 1993-919293	19930908
ZA 9307096	A	19950324	ZA 1993-7096	19930924
CN 1089908	A	19940720	CN 1993-118159	19930925
IL 107108	A1	19980104	IL 1993-107108	19930926
FI 9501379	A	19950323	FI 1995-1379	19950323
NO 9501138	A	19950324	NO 1995-1138	19950324
PRIORITY APPLN. INFO.:			DE 1992-4232755	19920926
			WO 1993-EP2432	19930908

AB Microcapsules for diagnostic or therapeutic use are prepd. comprising (1) a wall of biopolymer/synthetic polymer interpolymer, which has site-specific phys. properties or bears functional groups for binding e.g. **chelating ligands** or their metal complexes, and (2) an optional core consisting of a gas or therapeutic agent. Thus, an autoclaved gelatin soln. was adjusted to pH 5.0 and stirred with Bu cyanoacrylate to produce air-filled dispersible microparticles [55 mol% gelatin, 45 mol% poly(Bu cyanoacrylate)] for use in contrast media for sonog

L6 ANSWER 44 OF 68 USPATFULL
ACCESSION NUMBER: 94:88598 USPATFULL
TITLE: Lymphilized **ligand**-receptor complexes for assays and sensors
INVENTOR(S): Ligler, Frances S., Potomac, MD, United States
Whelan, James P., Potomac, MD, United States
PATENT ASSIGNEE(S): The United States of America as Represented by the Secretary of the Navy, Washington, DC, United States (U.S. government)
U.S. Drug Testing, Inc., Rancho Cucamonga, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5354654		19941011
APPLICATION INFO.:	US 1993-92818		19930716 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Saunders, David		
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1129		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A dry reagent prepared by lyophilizing a labelled **ligand** -immobilized receptor complex or a labelled receptor-immobilized **ligand** complex i.e., on rehydration, useful for detecting analytes in samples in a variety of displacement assays

L6 ANSWER 45 OF 68 MEDLINE
ACCESSION NUMBER: 95070174 MEDLINE
DOCUMENT NUMBER: 95070174 PubMed ID: 7979409
TITLE: Effect of processing inhibitors on cobalamin (vitamin B12) transcytosis in polarized opossum kidney cells.
AUTHOR: Ramanujam K S; Seetharam S; Dahms N M; Seetharam B
CORPORATE SOURCE: Department of Medicine, Medical College of Wisconsin, Milwaukee 53226.
CONTRACT NUMBER: DK-26438 (NIDDK)
SOURCE: ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, (1994 Nov 15) 315 (1) 8-15.
Journal code: 6SX; 0372410. ISSN: 0003-9861.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199412
ENTRY DATE: Entered STN: 19950110
Last Updated on STN: 19950110
Entered Medline: 19941216

AB The main objectives of the current study were to investigate the effect of tunicamycin and other post-translational processing inhibitors on the apical brush border expression of intrinsic factor-cobalamin receptor (IFCR) and the apical to basolateral transcytosis of cobalamin (Cbl). Because of the high and selective expression of IFCR in the apical brush border membrane of opossum kidney (OK) cells (K. S. Ramanujam, S. Seetharam, N. Dahms, and S. Seetharam, J. Biol. Chem. 266, 13135-13140), we have used cultured OK cells to address these issues. When polarized OK cells grown on culture inserts were incubated with tunicamycin, deoxynojirimycin, swainsonine, or ceruleni, the surface binding of the **ligand**, intrinsic factor-[56Co]Cbl was inhibited by tunicamycin but not by the other inhibitors. However, Cbl transcytosis was inhibited by both tunicamycin and ceruleni but not with deoxynojirimycin or swainsonine. Incubation of cells with tunicamycin decreased the half-life of IFCR from 48 to 24 h, thus causing faster degradation and depletion of the surface receptor. Incubation of cells with ceruleni resulted in the intralysosomal retention of internalized Cbl. Mature receptor labeled with either [35S]methionine or [3H]mannose was sensitive to digestion with both endoglycosidase H and **peptide** N-glycosidase F and revealed the presence of two or three N-linked oligosaccharides of the high mannose or hybrid type. Metabolic labeling of OK cells with [3H]palmitic acid revealed that IFCR was palmitoylated and the label was sensitive to treatment with hydroxylamine. Based on these results we suggest that IFCR expression in the apical membrane and Cbl transcytosis in polarized OK cells are regulated by core N-glycosylation but not by further processing of the terminal sugars. In addition, we also suggest that the inhibition of Cbl transcytosis by ceruleni is due to inhibition of post-internalization events.

L6 ANSWER 46 OF 68 USPATFULL
ACCESSION NUMBER: 93:72236 USPATFULL
TITLE: Nucleophilic polysubstituted aryl acridinium esters and uses thereof
INVENTOR(S): Law, Say-Jong, Westwood, MA, United States
PATENT ASSIGNEE(S): Ciba Corning Diagnostics Corp., Medfield, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5241070		19930831
APPLICATION INFO.:	US 1992-871601		19920417 (7)
DISCLAIMER DATE:	20070417		
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1988-249620, filed on 26 Sep 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Daus, Donald G.		
LEGAL REPRESENTATIVE:	Morgenstern, Arthur S., Klepchuk, Jr., Nicholas I.		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 15 Drawing Page(s)		
LINE COUNT:	1023		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to novel nucleophilic polysubstituted aryl acridinium esters and to novel conjugates thereof. The novel nucleophilic polysubstituted aryl acridinium esters and novel conjugates thereof are useful in biological assays, including novel assays for the determination of Vitamin B sub.12, folate, cortisol, estradiol, and thromboxane B sub.2.

L4 ANSWER 47 OF 68 USPATFULL
ACCESSION NUMBER: 93:61207 USPATFULL
TITLE: Method for the prescreening of drugs targeted to the V3
hypervariable loop of the HIV-1 envelope glycoprotein gp 120
INVENTOR(S): Neurath, Alexander R., 230 E. 79th St., New York, NY, United States 10021
Strick, Nathan, 3241 Lawrence Ave., Oceanside, NY, United States 11572
Rabenfeld, Paul, 1666 52nd St., Brooklyn, NY, United States 11204
Jiang, Shibo, 316 W. 98th St. Apr. 52S, New York, NY, United States 10025

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5232938		19930727
APPLICATION INFO.:	US 1991-735640		19910726 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rucker, Christine M.		
ASSISTANT EXAMINER:	Stucker, Jeffrey		
LEGAL REPRESENTATIVE:	Fruhauf, Holtz, Goodman & Woodward		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	7		
NUMBER OF DRAWINGS:	19 Drawing Figure(s); 13 Drawing Page(s)		
LINE COUNT:	1592		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the rapid screening of a drug targeted to the V3 hypervariable loop of the human immunodeficiency virus type 1 or type 2 envelope glycoprotein gp 120 comprising measuring the inhibitory effect of the drug on the interaction between gp 120 (or an antigen comprising the V3 hypervariable loop of HIV 1 gp 120 or HIV 2 gp 120) and antibodies specific for the V3 hypervariable loop, and anti-HIV chemotherapy with drugs binding to the V3 hypervariable loop.

L4 ANSWER 48 OF 68 USPATFULL
ACCESSION NUMBER: 93:79787 USPATFULL
TITLE: Method and composition for double receptor, specific binding assays
INVENTOR(S): Bunting, James R., Washington, DC, United States
PATENT ASSIGNEE(S): Baxter Diagnostics Inc., Deerfield, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 34394		19930928
	US 4271240		19810602 (Original)
APPLICATION INFO.:	US 1990-439020		19901118 (7)
	US 1978-930130		19780801 (Original)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1989-363814, filed on 9 May 1989 And a continuation-in-part of Ser. No. US 1978-871478, filed on 23 Jan 1978, now abandoned
DOCUMENT TYPE:	Reissue		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rucker, Christine M.		
ASSISTANT EXAMINER:	Preston, David H.		
LEGAL REPRESENTATIVE:	Patterson & Keough		
NUMBER OF CLAIMS:	46		
EXEMPLARY CLAIM:	1,46		
LINE COUNT:	1161		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The performance of double receptor, specific binding assays is improved by use of a receptor complex having the structure

A.sub.BL (BL)$sub.n A.sub.1

wherein BL is a binding **ligand**, A.sub BL is a receptor specific for binding **ligand**, A.sub.1 is a receptor, BL is covalently bonded to A.sub.1 and A.sub.BL is reversibly bonded to BL. Generally A.sub.BL is absorbed onto an insoluble surface and A.sub.1 is an antibody to the substance being assayed. The complex has particular utility in coated tube and rechargeable radioimmunoassay systems.

L4 ANSWER 49 OF 68 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1992:620158 CAPLUS
DOCUMENT NUMBER: 117:220158
TITLE: A system for enhanced in vivo clearance of diagnostic and/or therapeutic agents by extracorporeal depletion
INVENTOR(S): Nilsson, Rune, Lindgren, Lars; Norrgren, Kristina; Sandberg, Bengt, Bjergren, Hans Olof; Strand, Sven Erik
PATENT ASSIGNEE(S): Swed.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9212730	A1	19920806	WO 1992-SE20	19920115
W: CA, FI, JP, NO, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
SE 9100142	A	19920718	SE 1991-142	19910117
CA 2100256	AA	19920718	CA 1992-2100256	19920115
EP 567514	A1	19931103	EP 1992-903020	19920115
EP 567514	B1	19990331		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06504542	T2	19940526	JP 1992-503119	19920115
AT 178214	E	19990415	AT 1992-903020	19920115
ES 2130167	T3	19990701	ES 1992-903020	19920115
US 6253394	B1	20010626	US 1993-90047	19930312
PRIORITY APPLN. INFO.:			SE 1991-142	A 19910117
			WO 1992-SE20	W 19920115

AB Non-tissue bound targeting mole., selective for certain tissues or cells, intended for diagnostic and/or therapeutic applications are removed from blood or reduced to a lower concn. by an extracorporeal system contg. immobilized agents (e.g. receptors) which selectively bind the targeting mole. Targeting mole. are antibodies or their fragments conjugated with cytotoxic drugs, **radioisotopes** or activators of prodrugs, i.e. enzymes.

L4 ANSWER 50 OF 68 BIOSIS COPYRIGHT 2001 BIOSIS
ACCESSION NUMBER: 1993:34784 BIOSIS
DOCUMENT NUMBER: PREV199395022944
TITLE: IGF-I binding and IGF-I mRNA expression in the post-ischemic regenerating rat kidney.
AUTHOR(S): Matejka, Goran L. (1); Jennische, Eva
CORPORATE SOURCE: (1) Dep. of Histol., Univ. of Goteborg, Goteborg Sweden
SOURCE: Kidney International, (1992) Vol. 42, No. 5, pp. 1113-1123
ISSN: 0085-2538.
DOCUMENT TYPE: Article
LANGUAGE: English
AB The localization of IGF-I **peptide** and IGF-I mRNA was investigated in the post-ischemic regeneration rat kidney using immunohistochemistry and non **radioactive** in situ hybridization techniques. In addition, the distribution and relative quantity of IGF-I binding sites were studied by autoradiographic **ligand**-binding techniques. Two and three days after the injury, morphological signs of an intense regenerative activity was evident. By this time a substantial number of the regenerating cells were stained with a monoclonal antibody against the M1 subunit of ribonucleotide reductase, a proliferative marker used. Low proliferative tubular cells, replacing those that had been injured, were seen lining the tubular basement membrane. By seven days, the morphology in the cortex was quite normalized while cells of S2 segments in the outer medulla remained dedifferentiated. The regenerative cells expressed IGF-I **peptide** and IGF-I mRNA in a transient manner and this was found to correlate better to cell differentiation than cell division. In addition, non-tubular cells, predominantly macrophages, expressed both the IGF-I **peptide** and the mRNA. The IGF-I binding was significantly increased in the regenerative zone at all times studied and began to decline at day seven. The binding characteristics were found to be compatible with binding to the IGF-I receptor. Altogether, these findings provide circumstantial evidence that IGF-I is of tropic importance in the regeneration of renal tubular cells. The data are compatible with a local production and action of IGF-I, suggesting an autocrine and/or paracrine mode of action during the regenerative process.

L6 ANSWER 51 OF 68 USPATFULL
ACCESSION NUMBER: 91:60741 USPATFULL
TITLE: Redox polymerization diagnostic test composition and method for immunoassay and nucleic acid assay
INVENTOR(S): Oster, Gerald, 243 W. 11th St., New York, NY, United States 10014
Davis, Baruch J., Mount Sinai Medical Center, 1 Gustav Levy Pl., New York, NY, United States 10029

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5035997		19910730
APPLICATION INFO.:	US 1989-312525		19890217 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Marschel, Ardin H.		
LEGAL REPRESENTATIVE:	Sprung Horn Kramer & Woods		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	747		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A diagnostic test composition for detecting and measuring an analyte possessing biologic activity, the composition comprising

(a) A redox catalyst system capable of converting a monomer to a polymer, the monomer capable of undergoing addition polymerization, the redox catalyst system comprising one or more chemical moieties with

1) the analyte comprising at least one such moiety or

2) in the case that the analyte lacks a redox catalyst property, the analyte is linked by a specific ligand to at least one such moiety or is linked by the specific ligand to a generator of at least one such moiety, and

(b) at least one monomer capable of undergoing addition polymerization.

L6 ANSWER 52 OF 68 USPATFULL
ACCESSION NUMBER: 91:42637 USPATFULL
TITLE: Photopolymerization diagnostic test composition and method for immunoassay and nucleic acid assay
INVENTOR(S): Oster, Gerald, 241 W. 11th St., New York, NY, United States 10014
Davis, Baruch J., Mount Sinai Medical Center, 1 Gustave
Levy Pl., New York, NY, United States 10029

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5019496		19910528
APPLICATION INFO.:	US 1989-312544		19890217 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Marschel, Ardin H.		
LEGAL REPRESENTATIVE:	Sprung Horn Kramer & Woods		
NUMBER OF CLAIMS:	40		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1091		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A diagnostic test composition for detecting and measuring an analyte possessing biologic activity comprising

(a) a photocatalyst system capable of converting a monomer to a polymer upon exposure to light, the monomer capable of undergoing addition polymerization, the photocatalyst system comprising one or more chemical
moieties, with

(1) the analyte comprising at least one such moiety or generating at least one such moiety or

(2) in the case that the analyte lacks a photocatalyst property, the analyte is linked by a specific ligand to at least one such moiety or is linked by the specific ligand to a generator of at least one such moiety and

(b) at least one monomer capable of undergoing addition polymerization.

L6 ANSWER 53 OF 68 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 91108459 EMBASE
DOCUMENT NUMBER: 1991108459
TITLE: Ligand-exchange radiochromatographic resolution of [3H]DL-valine, [3H]DL-leucine and [3H]DL-methionine using a reverse-phase column in the presence of cupric acetate and GMP or cyanocobalamin.
AUTHOR: Fukuhara T.; Inoyama M.; Tanaka M.; Yuasa S.
CORPORATE SOURCE: Department of Biology, College of General Education, Osaka University,Osaka 560, Japan
SOURCE: Applied Radiation and Isotopes, (1991) 42/5 (457-462). ISSN: 0883-2889 CODEN: ARISEF
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal, Article
FILE SEGMENT: 023 Nuclear Medicine
029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English
AB [3H]DL-valine, [3H]DL-leucine and [3H]DL-methionine were resolved using ligand exchange chromatography (reverse phase) in the presence of cupric acetate (Cu(II)), and 5'-guanosine monophosphate or cyanocobalamin.
The assignment of the resolved enantiomers was carried out by means of co chromatography with non-labeled DL-amino acids after modifying them with fluorodinitrobenzene. The optical purity of the enantiomers was estimated to be greater than 99% The resolved enantiomers
were subjected to bioassay, which showed that the enantiomers were biochemically active.

L6 ANSWER 54 OF 68 USPATFULL
ACCESSION NUMBER: 90:54554 USPATFULL
TITLE: Assay for sulfhydryl amino acids and methods for detecting and distinguishing cobalamin and folic acid deficiency
INVENTOR(S): Allen, Robert H., Englewood, CO, United States
Stabler, Sally P., Denver, CO, United States
Lindenbaum, John, New York, NY, United States
PATENT ASSIGNEE(S): University Patents, Inc., Westport, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4940658		19900710
APPLICATION INFO.:	US 1986-933552		19861120 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kepplinger, Esther M.		
ASSISTANT EXAMINER:	Schreiner, Toni R.		
LEGAL REPRESENTATIVE:	Pahnke & Associates		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	18		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	2375		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Method for determining levels of sulfhydryl amino acids, particularly total homocysteine levels in samples of body tissue from warm-blooded animals, methods of detecting cobalamin and folic acid deficiency using an assay for total homocysteine levels, and methods for distinguishing cobalamin from folic acid deficiency using an
assay for total homocysteine levels in conjunction with an assay for methylmalonic acid

L4 ANSWER 55 OF 68 USPATFULL
ACCESSION NUMBER: 90.15471 USPATFULL
TITLE: Cascade immunoassay by multiple binding reactions
INVENTOR(S): Mapes, James P., Raleigh, NC, United States
Hoke, Randal A., Cary, NC, United States
PATENT ASSIGNEE(S): Becton, Dickinson and Company, Franklin Lakes, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4904583		19900227
APPLICATION INFO.:	US 1987-53896		19870526 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Marsden, Robert J.		
ASSISTANT EXAMINER:	Spiegel, Jack		
LEGAL REPRESENTATIVE:	Brown, Richard E.		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	785		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for enzyme immunoassay includes contacting under binding conditions a liquid suspected of containing an analyte, an antianalyte affixed to a solid support and a tracer having an enzyme conjugated thereto. A bound fraction is separated from the liquid and incubated in a second liquid with a masked ligand. The masked ligand is converted by the enzyme on the bound fraction to give free ligand which binds to an antiligand. A signal system, such as a signal enzyme and substrate therefor, or a label-loaded vesicle and vesicle lysing agent, is added to generate a signal used to detect or measure the analyte in the liquid. The invention includes a kit of materials useful in performing the assay of the invention.

L4 ANSWER 56 OF 68 USPATFULL
ACCESSION NUMBER: 87.69949 USPATFULL
TITLE: Enzymatic reactions using magnetic particles
INVENTOR(S): Whitehead, Roy A., Hingham, MA, United States
Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4698302		19871006
APPLICATION INFO.:	US 1985-744457		19850613 (6)
RELATED APPLN. INFO.:	Division of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554088		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Foelak, Morton		
ASSISTANT EXAMINER:	Nutter, Nathan M.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1464		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process is provided for the preparation of magnetic particles to which

a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.

L4 ANSWER 57 OF 68 USPATFULL
ACCESSION NUMBER: 87.66802 USPATFULL
TITLE: Magnetic particles for use in separations
INVENTOR(S): Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
Whitehead, Roy A., Hingham, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4695392		19870922
APPLICATION INFO.:	US 1985-744434		19850613 (6)
RELATED APPLN. INFO.:	Division of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554088		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Foelak, Morton		
ASSISTANT EXAMINER:	Nutter, Nathan M.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1514		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process is provided for the preparation of magnetic particles to which

a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.

L4 ANSWER 58 OF 68 USPATFULL
ACCESSION NUMBER: 87.66801 USPATFULL
TITLE: Magnetic particles for use in separations
INVENTOR(S): Whitehead, Roy A., Hingham, MA, United States
Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4695392		19870922
APPLICATION INFO.:	US 1985-744434		19850613 (6)
RELATED APPLN. INFO.:	Division of Ser. No. US 1983-493991, filed on 12 May 1983, now patented, Pat. No. US 4554088		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kight, John		
ASSISTANT EXAMINER:	Nutter, Nathan M.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1459		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process is provided for the preparation of magnetic particles to which

a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations

L4 ANSWER 59 OF 68 USPATFULL
ACCESSION NUMBER: 87:41600 USPATFULL
TITLE: Magnetic particles for use in separations
INVENTOR(S): Josephson, Lee, Arlington, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4672040		19870609
APPLICATION INFO.:	US 1985-746692		19850618 (6)
DISCLAIMER DATE:	20021118		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1983-491991, filed on 12 May 1983, now patented, Pat. No. US 4554088 And Ser. No. US 1985-746351, filed on 13 Jun 1985, now patented, Pat. No. US 4628027 And Ser. No. US 1985-744435, filed on 13 Jun 1985 And Ser. No. US 1985-744434, filed on 13 Jun 1985 And Ser. No. US 1985-744457, filed on 13 Jun 1985		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Nucker, Christine M.		
ASSISTANT EXAMINER:	Wieder, Stephen C.		
LEGAL REPRESENTATIVE:	Fennie & Edmonds		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1770		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are provided for the use of magnetically responsive particles in systems in which the separation of certain molecules, macromolecules and cells from the surrounding medium is desirable. The magnetically responsive particles may be coupled to a wide variety of molecules. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused.

L4 ANSWER 60 OF 68 USPATFULL
ACCESSION NUMBER: 87:41588 USPATFULL
TITLE: Compositions and method for simultaneous multiple assay of analytes using **radioisotope** **chelate** labels
INVENTOR(S): Olson, Douglas E., Doylestown, PA, United States
PATENT ASSIGNEE(S): ICN Micromedic Systems, Inc., Costa Mesa, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4672028		19870609
APPLICATION INFO.:	US 1984-612979		19840523 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Nucker, Christine M.		
LEGAL REPRESENTATIVE:	Lyon & Lyon		
NUMBER OF CLAIMS:	47		
EXEMPLARY CLAIM:	1		
LINE COUNT:	764		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds useful in a simultaneous multiple assay for analytes such as steroids, proteins, **peptides**, carbohydrates or drugs. The compound or compounds are prepared by labelling an individual analyte with a **radioisotope** through a **chelating** agent to form a coordinated compound. The assay uses one or more **chelated** labelled analytes with one or more labelled analytes wherein each **radioisotope** is different.

L4 ANSWER 61 OF 68 USPATFULL
ACCESSION NUMBER: 86:60974 USPATFULL
TITLE: Binding assays employing magnetic particles
INVENTOR(S): Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
Whitehead, Roy A., Hingham, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4628037		19861209
APPLICATION INFO.:	US 1985-744351		19850613 (6)
RELATED APPLN. INFO.:	Division of Ser. No. US 1983-491991, filed on 12 May 1983, now patented, Pat. No. US 4554088		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Nucker, Christine M.		
ASSISTANT EXAMINER:	Wieder, Stephen C.		
LEGAL REPRESENTATIVE:	Fennie & Edmonds		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1495		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process is provided for the preparation of magnetic particles to which a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.

L6 ANSWER 62 OF 68 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1986:84931 CAPLUS
DOCUMENT NUMBER: 104:84931
TITLE: Simultaneous multiple assays and compounds and compositions useful in them
INVENTOR(S): Olson, Douglas Richard
PATENT ASSIGNEE(S): Micromedic Systems, Inc., USA
SOURCE: Eur. Pat. Appl., 24 pp.
CODEN: EPXADW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 165716	A1	19851227	EP 1985-303564	19850521
EP 165716	B1	19900131		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4672028	A	19870609	US 1984-612979	19840523
AT 50066	E	19900215	AT 1985-303564	19850521
AU 8542798	A1	19851128	AU 1985-42798	19850523
AU 589370	B2	19890914		
JP 61060092	A2	19860326	JP 1985-111312	19850523
PRIORITY APPLN. INFO.:			US 1984-612979	19840523
			EP 1985-303564	19850521

AB Simultaneous multiple assays for org. species (e.g., steroids, proteins, **peptides**, carbohydrates, drugs) are described. This procedure makes use of coordinated compds., which are prepd. by labeling an individual org. species with a **radioisotope** through a **chelating** agent of general structure (HO2CCH2)2NCHR1CH2N(CH2CO2H)CH2CH2N(CH2CO2H)2 where R = H, a substituted with NO2, NH2, and/or SO3H and n = 0 or 1. **Radiolabeled** org. species comp. individually distinguishable **radionuclides** are combined in a variety of configurations to measure more org. species simultaneously using radioassay. For example, for simultaneous detn. of LH and FSH, 57Co-labeled LH was prepd. by mixing lyophilized LH with diethylenetriaminepentacetic anhydride (I) in NaHCO3 soln. The resulting LH-I was mixed with 57CoCl2 in HCl to yield 57Co-labeled LH. 125I-labeled FSH was prepd. by mixing FSH antigen with Na125I in phosphate-buffered saline. A test sample or std. was mixed with antiserum and incubated for 1 h at 37 degrees. Tracer soln. were added and the reaction mixt. was further incubated for 1 h at room temp. After addn. of ppts. soln., the mixt. was incubated for 10 min at room temp. and centrifuged. The liq. was discarded and the tubes were counted for 125I and 57Co in a gamma-counter. Unknown samples were read from a std. curve.

L6 ANSWER 63 OF 68 USPATFULL
ACCESSION NUMBER: 85:66137 USPATFULL
TITLE: Magnetic particles for use in separations
INVENTOR(S): Whitehead, Roy A., Hingham, MA, United States
Chagnon, Mark S., Lowell, MA, United States
Groman, Ernest V., Brookline, MA, United States
Josephson, Lee, Arlington, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4554088		19851119
APPLICATION INFO.:	US 1983-492881		19830512 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Demers, Arthur P.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1501		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process is provided for the preparation of magnetic particles to which a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.

L6 ANSWER 64 OF 68 USPATFULL
ACCESSION NUMBER: 84:35942 USPATFULL
TITLE: Detecting intrinsic factor blocking Rlx antibody
INVENTOR(S): Ellis, James E., Stoughton, MA, United States
Lidgard, Graham P., Wellesley, MA, United States
Odstrchel, Gerald, Walpole, MA, United States
Riceberg, Louis J., Needham, MA, United States
PATENT ASSIGNEE(S): Corning Glass Works, Corning, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4447528		19840508
APPLICATION INFO.:	US 1981-293354		19810810 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Marsnti, Sidney		
LEGAL REPRESENTATIVE:	Maycock, W. E.		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
LINE COUNT:	395		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A radioassay procedure and reagent kit therefor for detecting auto blocking antibody, such as auto blocking antibody which interferes with the complexation of intrinsic factor with vitamin B sub.12. A receptor, i.e., intrinsic factor, is immobilized on a support and the amount of ligand, i.e., vitamin B sub.12, capable of binding therewith in the presence of a biological fluid sample is determined.

L6 ANSWER 65 OF 68 USPATFULL
ACCESSION NUMBER: 81:30332 USPATFULL
TITLE: Method and composition for double receptor, specific binding assays
INVENTOR(S): Bunting, James R., Washington, DC, United States
PATENT ASSIGNEE(S): Baxter Travenol Laboratories, Inc., Deerfield, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4271140		19810602
APPLICATION INFO.:	US 1978-930130		19780801 (5)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1976-671476, filed on 23 Jan 1976, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Padgett, Benjamin R.		
ASSISTANT EXAMINER:	Nucker, Christine M.		
LEGAL REPRESENTATIVE:	Flattery, Paul C., Flynn, Lawrence M., Hensley, Max D.		
NUMBER OF CLAIMS:	45		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1050		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The performance of double receptor, specific binding assays is improved by use of a receptor complex having the structure

A.sub.BL (BL) sub.n A.sub.1

wherein BL is a binding ligand, A.sub.BL is a receptor specific for binding ligand, A.sub.1 is a receptor, BL is covalently bonded to A.sub.1 and A.sub.BL is reversably bonded to BL. Generally A.sub.BL is absorbed onto an insoluble surface and A.sub.1 is an antibody to the substance being assayed. The complex has particular utility in coated tube and rechargeable radioimmunoassay systems.

L6 ANSWER 66 OF 68 USPATFULL
ACCESSION NUMBER: 81:27515 USPATFULL
TITLE: Automated direct serum radioassay
INVENTOR(S): Reese, Max, Salt Lake City, UT, United States
PATENT ASSIGNEE(S): Becton Dickinson & Company, Paramus, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4266494		19810519
APPLICATION INFO.:	US 1978-920801		19780630 (5)
DISCLAIMER DATE:	19950922		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1977-774290, filed on 4 Mar 1977, now patented, Pat. No. US 4108976		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schafer, Richard E.		
ASSISTANT EXAMINER:	Nucker, Christine M.		
LEGAL REPRESENTATIVE:	Mark, Louis E., Olstein, Elliot M.		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
LINE COUNT:	499		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Automated radioassay in which a serum is diluted and pre-incubated in the presence of a radioactive labeled ligand, such as an antigen, and a binder, such as an antibody, specific to the ligand. The pre incubated mixture is flowed through a chamber containing binder specific to the ligand supported on a solid support, and the labeled and unlabeled ligand not bound to the binder in pre-incubation are bound to the receptor on flow through the chamber. An eluting solution is flowed through the chamber to release the ligand bound to the binder in the chamber for reuse thereof. By counting the radioactivity of one or both of the fraction which flows through the chamber or which is subsequently released therefrom the quantity of a specific ligand in the serum may be assayed.

L6 ANSWER 67 OF 68 USPATFULL
ACCESSION NUMBER: 78:53922 USPATFULL
TITLE: In vitro diagnostic test
INVENTOR(S): Ichakiseloe, Dionysele S., St. Paul, MN, United States
PATENT ASSIGNEE(S): Minnesota Mining and Manufacturing Company, St. Paul, MN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4115534		19780919
APPLICATION INFO.:	US 1977-808339		19770620 (5)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1976-715933, filed on 19 Aug 1976, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Padgett, Benjamin R.		
ASSISTANT EXAMINER:	Mucker, Christine M.		
LEGAL REPRESENTATIVE:	Alexander, C., Bell, Donald M., Lilly, James V.		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	804		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for determining the concentration of substances in biological fluids (e.g., drugs, hormones, vitamins and enzymes) is disclosed wherein magnetically responsive, permeable, solid, water-insoluble microparticles are employed

L6 ANSWER 68 OF 68 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1978:34141 CAPLUS
DOCUMENT NUMBER: 88:34141
TITLE: Detection of genetic variation with radioactive ligands. I. Electrophoretic screening of plasma proteins with a selected panel of compounds
AUTHOR(S): Cavelli-Sforza, Luigi L.; Darger, Stephen P.; Rummel, Diane J.
CORPORATE SOURCE: Dep. Genet., Stanford Univ. Med. Cent., Stanford, Calif., USA
SOURCE: Am. J. Hum. Genet. (1977), 29(6), 581-92
CODEN: AJHGAG
DOCUMENT TYPE: Journal
LANGUAGE: English

AB To detect new genetic variation in human plasma proteins, a panel of 63 radioactive substances were screened as potential radioligands using polyacrylamide gel electrophoresis and autoradiog. Vitamins, hormones, drugs, amino acids, purines, pyrimidines, sugars, and lipids labeled with 14C or other radionuclides were among those substances tested. A majority bound to albumin and a smaller fraction to prealbumins and lipoproteins. Several vitamins and hormones bound to specific .alpha. and .beta.-globulins. Electrophoretic polymorphisms of the vitamin D-binding protein (group-specific component), a vitamin B12-binding protein (transcobalamin II), and thyroxine-binding .alpha.-globulin were obsd. Testosterone-binding .beta.-globulin showed an electrophoretic polymorphism in Caucasians and a possible deficiency allele. Transcortin showed an electrophoretic doublet in all persons tested but no electrophoretic variation. A protein binding a deriv. of norepinephrine or epinephrine was identified as transferrin. A nonpolymorphic protein running cathodal to albumin and binding a deriv. of riboflavin was tentatively identified as a fraction of albumin with mobility altered as a result of interaction with the ligand.